Abstract 5519
Background
The elderly (above 65 years) have become the leading population of our society. Their multitude of healthcare chronic problems demands palliative care and therefore Palliative Care problems and needs (PCPN) assessment.
Methods
A quantitative study using structured questionnaires [PNPC, Mini – Mental State Examination (MMSE), demographic and clinical characteristics] was conducted through December 2018 – February 2019, at internal medicine wards of a public general hospital. Patients with MMSE<24, at the end of life and with recent surgery were excluded. A translated in Hellenic language short-form version of PCPN used assessing Palliative Care Problems and Need for Professional Care. The PCPN is a 33 items 3-point Likert type scale that covers 8 domains: Activities of daily living (ADL/IADL), Physical symptoms (PS), Autonomy (A), Social (SI), Psychological (PI), Spiritual issues (Sp), Financial problems (FP) and Need for information (NI). The level of statistical significance was set at 0.05.
Results
Sample consisted of 150 patients (51% men) with mean age 75.6 years old (SD = 10.1). The cancer diagnosis was 40% mostly colon cancer (38%) and for non-cancer patients hypertension (62.2%). No statistical differences were found between cancer and non cancer patients for the demographic and clinical characteristics (p > 0.05). The mean MMSE scare was 27.2 (SD = 2) in patients with cancer and 27.6 (SD = 1.9) in patients with no cancer (p = 0.313). Significantly greater scores were found on the ADL/IADL (p=.012 - p=.001), A (p=.050 - p=.002), SI (p=.007 - p=.004) and Sp (p=.014 - p=.001) in the cancer group for both problems and needs for care. Additionally, the cancer patients reported statistically significant higher need for professional care for FP (p=.022). No statistically significant differences were found for PS, PI and NI (p>.050).
Conclusions
Elderly hospitalized cancer patients have more palliative care problems and needs for care at daily living, social, spiritual and financial issues than those with no cancer. Hence, nurses should focus on meeting these needs, based on the principles of PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract